For endometrial carcinoma, the highest cumulative risk was observed in the MSH6 mutation carriers (61%), while the cumulative risks for MLH1 and MSH2 mutation carriers were 25% and 49% respectively. This evidence concerns the gene MSH6 and endometrial carcinoma.